Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.


Sci. Signal., 29 March 2011
Vol. 4, Issue 166, p. ra18
[DOI: 10.1126/scisignal.2001314]


Editor's Summary

When Negative Feedback Fails
Bcr-Abl is a fusion protein with tyrosine kinase activity that causes some forms of leukemia. Bcr-Abl activates Src family tyrosine kinases (SFKs), but resistance to drugs, such as dasatinib and imatinib, that target Bcr-Abl and SFKs limits their clinical usefulness. With global tyrosine phosphoproteomic analysis in a murine leukemia cell line model, Rubbi et al. identified several negative feedback mechanisms that limited SFK activity and showed that their effectiveness was blunted by Bcr-Abl. Sensitivity of human leukemia cell lines to imatinib correlated with the amount of negative feedback signaling to SFKs. By exploring the mechanisms by which Bcr-Abl overpowered the negative feedback, the authors identified potential therapeutic targets for treating leukemias resistant to Bcr-Abl and SFK inhibitors or that may be combined with these tyrosine kinase inhibitors to prevent the development of resistance.

Citation: L. Rubbi, B. Titz, L. Brown, E. Galvan, E. Komisopoulou, S. S. Chen, T. Low, M. Tahmasian, B. Skaggs, M. Müschen, M. Pellegrini, T. G. Graeber, Global Phosphoproteomics Reveals Crosstalk Between Bcr-Abl and Negative Feedback Mechanisms Controlling Src Signaling. Sci. Signal. 4, ra18 (2011).

Read the Full Text

Clinical Targeting of Mutated and Wild-Type Protein Tyrosine Kinases in Cancer.
J. M. Drake, J. K. Lee, and O. N. Witte (2014)
Mol. Cell. Biol. 34, 1722-1732
   Abstract »    Full Text »    PDF »
Glucose deprivation activates a metabolic and signaling amplification loop leading to cell death.
N. A. Graham, M. Tahmasian, B. Kohli, E. Komisopoulou, M. Zhu, I. Vivanco, M. A. Teitell, H. Wu, A. Ribas, R. S. Lo, et al. (2014)
Mol Syst Biol 8, 589
   Abstract »    Full Text »    PDF »
Metastatic castration-resistant prostate cancer reveals intrapatient similarity and interpatient heterogeneity of therapeutic kinase targets.
J. M. Drake, N. A. Graham, J. K. Lee, T. Stoyanova, C. M. Faltermeier, S. Sud, B. Titz, J. Huang, K. J. Pienta, T. G. Graeber, et al. (2013)
PNAS 110, E4762-E4769
   Abstract »    Full Text »    PDF »
Temporal Profiling of Lapatinib-suppressed Phosphorylation Signals in EGFR/HER2 Pathways.
K. Imami, N. Sugiyama, H. Imamura, M. Wakabayashi, M. Tomita, M. Taniguchi, T. Ueno, M. Toi, and Y. Ishihama (2012)
Mol. Cell. Proteomics 11, 1741-1757
   Abstract »    Full Text »    PDF »
TSLP Signaling Network Revealed by SILAC-Based Phosphoproteomics.
J. Zhong, M.-S. Kim, R. Chaerkady, X. Wu, T.-C. Huang, D. Getnet, C. J. Mitchell, S. M. Palapetta, J. Sharma, R. N. O'Meally, et al. (2012)
Mol. Cell. Proteomics 11, M112.017764
   Abstract »    Full Text »    PDF »
Oncogene-specific activation of tyrosine kinase networks during prostate cancer progression.
J. M. Drake, N. A. Graham, T. Stoyanova, A. Sedghi, A. S. Goldstein, H. Cai, D. A. Smith, H. Zhang, E. Komisopoulou, J. Huang, et al. (2012)
PNAS 109, 1643-1648
   Abstract »    Full Text »    PDF »
Science Signaling Podcast: 29 March 2011.
T. G. Graeber and A. M. VanHook (2011)
Science Signaling 4, pc6
   Abstract »    Full Text »

To Advertise     Find Products

Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882